Sensyne Health

The Clinical AI Company

Interim Report 2021

Sensyne Health Interim Results

Oxford, UK; 21 January 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, today announces its Interim Results for the six months ended 31 October 2020.

Lord (Paul) Drayson, CEO of Sensyne Health, commented:

"I am pleased to report that Sensyne has made significant commercial progress over the past six months and has achieved several key milestones in the development of its research partnerships with NHS Trusts and in its work for leading pharmaceutical companies applying Clinical AI to improve patient care and accelerate life sciences research. I am particularly pleased with the results we have been able to achieve during the COVID-19 pandemic.

In January we completed a £27.5 million fund-raising, signed an important strategic collaboration with Phesi Inc and in December launched our GDm-Health product in the United States. We have made a strong start to the New Year and are well placed to build on this momentum in 2021."

OPERATING HIGHLIGHTS (INCLUDING POST PERIOD END)

Growth of anonymised NHS patient dataset to 6.8m records to achieve IPO target

- Four new strategic research agreements with Somerset, Hampshire, Milton Keynes University and Royal Wolverhampton NHS Trusts signed between October 2020 and January 2021 to provide access to an aggregate of 2.95m records.
- Data access agreement with NHS Greater Glasgow and Clyde NHS Trust to provide access to 1.1m anonymised patient datasets in three specific disease areas including cardiovascular disease signed in October 2020

Discovery Sciences: New commercial agreements expand relationships with pharmaceutical industry

- Collaboration agreement with Alexion to study the prevalence and outcomes of patients in certain disease areas signed in May 2020
- Research collaboration signed with Bristol Myers Squibb in October 2020

Software Products: Clinical algorithm platform and remote monitoring products

- Launch of SENSE™ clinical algorithm platform to provide real-time clinical decision and operational support launched in September 2020
- First algorithm to provide personalised care for COVID-19 patients developed in partnership with the Chelsea and Westminster Hospital NHS Foundation Trust
- Launch in the US of GDm-Health™ for diabetes in pregnancy in December 2020
- Launch of MagnifEye™, a new software application using deep machine learning AI to automate the accurate reading of lateral flow diagnostic tests launched in January 2021

Planned scaling and industrialisation of data platforms

- Targeting an expansion of the NHS patient datasets to c.12.5m records by the end of December 2022 to provide critical mass to target post approval Phase 4 clinical trials
- Development of SENSIGHT™, a real-world-data analytics platform for the support of R&D from drug discovery through to clinical trials, post market approval and drug launch
- Rapid expansion of SENSE platform to expand offering to global healthcare providers and payers

Phesi Strategic Collaboration

- Strategic collaboration with Phesi, Inc., a US-based specialist clinical trials data company, commenced on 5 January 2021 (following the close of fundraising, see Financial highlights)
- Provides access to c.13.5m patient records from c.320,000 clinical trials completed since 2007 to create an enhanced offering to pharmaceutical and biotechnology clients including improving the design and efficiency of clinical programmes
- Initial five-year term for the collaboration with Sensyne making a $10m equity investment into Phesi with these proceeds contractually supporting collaboration activities and enhancing their clinical trials data analytics offering

Strengthening of Board and Senior Management team

- Several key appointments to strengthen the senior management team including Michael Macdonnell as Chief Operating Officer, Derek Baird as President of North America, Laura Hillier as General Counsel and Company Secretary and Dr Richard Pye as Chief Investment Officer
- Mr Tony Bourne to become a Non-Executive Director commencing 31 January 2021

FINANCIAL HIGHLIGHTS

- Successfully completed a £27.5 million fundraise post period end in January 2021 that is expected to enable the Group to industrialise its data analytics capability, enter into an exclusive strategic collaboration with Phesi and strengthen its balance sheet for future partnering discussions

- Total revenues of £2.3m for the six months ended 31 October 2020 (HY20: £0.4m)

- Total research and development expenditure of £7.7m, of which £0.3m was capitalised for the six months ended 31 October 2020 (HY20: £5.4m, of which £0.2m was capitalised)

- Adjusted operating loss from continuing operations of £9.5m for the six months ended 31 October 2020 (HY20: £7.4m)

- Cash used in operations of £12.5m for the six months ended 31 October 2020 (HY20: £7.7m)

- Operating loss of £13.6m for the six months ended 31 October 2020 (HY20: £9.8m)

- Cash and cash equivalents of £18.6m at 31 October 2020 (FY20: £31.7m)

Analyst and Investor briefing

Management will present the interim results for analysts and investors today at 13.00 GMT. There will be a simultaneous live conference call and webcast. For more details please contact radu@consilium-comms.com at Consilium Strategic Communications.

A replay of today's webcast of the meeting and the presentation slides will be available on the investor section of Sensyne Health's website after the event at https://www.sensynehealth.com/investors/investor-hub

-ENDS-

For more information please contact:

Sensyne Health (www.sensynehealth.com)	**+44 (0) 330 058 1845**
Lord (Paul) Drayson PhD FREng, Chief Executive Officer	
Michael Norris, Interim Chief Financial Officer	
Dr Richard Pye, Chief Investment Officer	
Peel Hunt LLP (Nominated Adviser and Joint Broker)	**+ 44 (0) 20 7418 8900**
Dr Christopher Golden	
James Steel	
Oliver Jackson	
Liberum (Joint Broker)	**+ 44 (0) 20 3100 2000**
Bidhi Bhoma	
Euan Brown	
Consilium Strategic Communications	**+44 (0) 20 3709 5700**
Mary-Jane Elliott	
Sukaina Virji	
Davide Salvi	
sensynehealth@consilium-comms.com	

About Sensyne Health
Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

For more information, please visit: www.sensynehealth.com

Operating Review

Overview

The half year and post period has been one of strong momentum across the business as Sensyne delivered on key operational and corporate milestones while expanding technology innovation and diversifying the therapeutic areas we work in. This progress enabled completion in December 2020 of a £27.5 million fundraise that will enable us to implement our plans for accelerating the growth and development of the business through the industrialisation and scaling of our data platforms to enhance our offering to the healthcare and life science industries. We were pleased by the level of support from new and existing institutional shareholders in the placing and our existing retail shareholders in the over-subscribed open offer.

Sensyne operates two business units. Sensyne's Discovery Sciences division uses clinical AI to optimise clinical trials and undertake research and development of new medicines through the analysis of its growing real-world patient data. The Software Products division focuses on providing clinical AI tools and patient monitoring software to healthcare providers.

Underpinning these business units is our unique partnership with the NHS whereby the Group has access on an anonymised basis to a growing database of unique, longitudinal patient records. Our ethical and transparent partnership model sees the NHS Trust that partner with Sensyne receiving an equity stake in the Group and a royalty on revenues that are generated from research undertaken under the strategic research agreements ("SRAs"). The progress made during the period shows this business model is working and is demonstrating its potential benefit to global health systems, clinicians and patients, along with the life science industry.

The COVID-19 pandemic and associated disruption to the provision of healthcare and undertaking of medical research and development have accelerated the interest in and adoption of digital medicine towards improvement in healthcare outcomes and research and development.

Expansion of anonymised patient records to achieve IPO target of 5 million

In November 2020, Sensyne achieved its IPO target of procuring an anonymised patient dataset of 5 million records. This significant milestone was achieved with the signing of two new SRAs with Milton Keynes University Hospital NHS Foundation Trust and Somerset NHS Foundation Trust in October and November respectively, plus in October entering into a data sharing agreement with NHS Greater Glasgow and Clyde that provided access to 1.1 million patient records across three therapeutic areas including cardiovascular disease. Sensyne has since signed a further two SRAs with Hampshire Hospitals NHS Foundation Trust in November 2020 and Royal Wolverhampton Trust in January 2021 to increase the size of our anonymised patents data sets to 6.8 million records. This is expected to further enable Sensyne to apply clinical artificial intelligence research on anonymised patient data to improve patient care in an ethical way and accelerate research into new medicines.

The growing data set has a 'multiplier effect' both in driving additional pharmaceutical partners to enter into commercial research agreements with Sensyne, and in attracting further NHS Trusts and health systems to enter into additional SRAs.

A key part of our industrialisation plans is the further growth in our real-world anonymised patient data sets. Sensyne is aiming to expand its NHS records to approximately 12.5 million unique patients by the end of December 2022. This enlarged figure represents approximately 20% of the UK population and is expected to provide the critical mass to expand its clinical tools offering to the life science industry to target involvement in post-approval Phase 4 clinical trials that can support reimbursement strategies, along with enhancing research into rare diseases. Sensyne is currently in discussions with multiple NHS Trusts who have access to an aggregate of c.27 million individual patient records.

Additionally, the Group is targeting the procurement of specialist datasets totalling approximately 5 million records by the end of December 2022. These additional records are intended to target both specific therapeutic areas while providing geographical diversity to support the regulatory requirements in different jurisdictions.

Discovery Sciences activity

Life Science Partnerships
Within Sensyne's Discovery Science division, the growth of the anonymised patient data will potentially enable Sensyne to cover a broader range of research across different clinical areas, deliver powerful data insights to speed up the development of novel approaches to new medicines, and develop AI-powered clinical decision support tools to improve patient care.

Sensyne has continued to expand its commercial research partnerships with the pharmaceutical industry. In October 2020, we signed an agreement with Bristol Myers Squibb who became the fourth major industry partner we are working with. Our existing commercial research agreements with pharmaceutical partners either continue to progress well or have finished. There are a broad range of pharmaceutical partnership opportunities in the pipeline, with active discussions taking place, particularly around the use of Sensyne's technology for clinical development and market access. Additionally there has been strong early interest and engagement with Phesi's pharmaceutical clients on the joint offering and more detailed conversations are progressing well.

Development of SENSIGHT™
A key to being able to accelerate our future growth by industrialising our data platform is the development of SENSIGHT for the life science industry. SENSIGHT is a real-world data analytics platform that can integrate anonymised patient data sets across a large number of sources including NHS Trusts to provide access to fully anonymised data to support all stages of research and development from drug discovery through to clinical trials and post market approval and drug launch.

SENSIGHT will standardise the anonymised patient data sets which Sensyne has access to, enabling the Group to accelerate the generation of insights, enhance existing products and offer new ones to the life science industry. For example, SENSIGHT will be able to support the development of 'synthetic control arms' in Phase 2 and Phase 3 clinical trials and drug target identification across a range of therapeutic areas. A crucial feature of SENSIGHT will be the significant increase in speed of interrogating these data to generate outputs for pharmaceutical clients.

Strategic collaboration with Phesi, Inc.
In January 2021, we entered into an exclusive strategic collaboration with the US based private company Phesi, Inc. ("Phesi") to provide a combined offering of clinical trial data and real-world data in synthetic clinical trial arms and clinical decision support tools. This strategic collaboration will also enhance Sensyne's strategy of industrialising and scaling its SENSIGHT platform as Phesi has done with its own platform.

The transaction with Phesi provides Sensyne with the benefit of a different type of data set: anonymised global clinical trials data and clinical investigator site information. Phesi has curated a large, and highly structured clinical trial database of approximately 13.5 million patient records from an estimated 320,000 global clinical trials that have completed since

2007. Phesi has developed a clinical trial analytics platform, including a clinical trial investigator site management tool called ClinSite, which is used to improve the design and efficiency of any clinical programme across all phases of development and multiple therapeutic areas.

A combination of the development of the SENSIGHT platform to develop new offerings for the pharmaceutical industry, including synthetic clinical trial control arms and clinical decision support tools and the collaboration with Phesi where joint discussions are taking place with existing and new pharmaceutical clients, is expected to drive a pipeline of future pharmaceutical commercial research collaborations.

The initial term of the exclusive strategic collaboration will be five years with an automatic renewal for successive two-year periods unless terminated. Joint projects with pharmaceutical company clients will be based on a revenue share model. Sensyne has made a $10 million investment into Phesi and received 10 per cent of Phesi’s fully-diluted share capital. The investment into Phesi will be used to enhance the Phesi clinical trials data analytics offering and activities that are connected to the strategic collaboration. Lord Drayson will join the Phesi board of directors.

Software Products activity

Sensyne’s Software Product division achieved a number of milestones during the period under review as the Group sought to support health systems’ response to the COVID-19 pandemic that has resulted in increased demand for the adoption of digital health solutions.

Launch of SENSE™ Platform
In September 2020, Sensyne announced the UK launch of ‘SENSE’, a clinical algorithm engine that emerged as a new part of the Software Products business, that was created in partnership with Microsoft to provide a real-time decision support service. SENSE generates AI algorithms, called SYNEs, for real-time decision support across multiple medical conditions. Developed by analysing large, anonymised patient datasets, SYNEs provide transparent, predictive insights that improve patient care and operational productivity, particularly in the context of healthcare workforce shortages.

The first SYNE developed was SYNE-COV™ that aims to provide more personalised care for patients with COVID-19 by integrating data into an existing real-time dashboard allowing clinicians to augment their clinical decisions with near real-time risk predictions pertaining to ICU admission, mechanical ventilation and in-hospital mortality.

SYNE-COV was co-developed by Sensyne and critical care clinicians at the Chelsea and Westminster Hospital through the analysis of real-world data collected in their A&E department. Sensyne is now, under MHRA directions, organising a prospective Clinical Investigation to provide further clinical evidence which will support CE marking of the device.

This is a timely example of the real-time predictions that SENSE can provide to clinicians and operational managers. Sensyne believes that the potential commercial opportunity for SENSE is substantial. As part of the Group’s industrialisation plans, it will be developing SENSE through the rapid expansion of the platform, whilst simultaneously benefiting from the increasing size of Sensyne’s real-world patient datasets.

Remote monitoring products
The pandemic has also accentuated demand for Sensyne’s remote monitoring products. Customers for GDm-Health™ (for diabetes in pregnancy) have grown and, as at 31 December 2020, it is now in use in over 50 of the NHS Trusts in England and has helped to care for over

16,000 babies born to diabetic mothers since its launch in November 2018. In December 2020, Sensyne launched GDm-Health in the US following an agreement with Cognizant to support the sale of digital health software products in this territory. Consequently, Sensyne is in a number of discussions with health systems and insurance companies introduced by Cognizant. Additionally, following the appointment of Derek Baird as President North America in November 2020 and the establishment of a US office, business development for GDm-Health in the US is being directly undertaken by Sensyne to complement Cognizant's activity.

In response to demand from our clinical partners, we also launched BPm-Health™ in May 2020, a remote monitoring system in the UK for the management of blood pressure in pregnancy, while DBm-Health™, a new software product for people with or at risk of diabetes was launched in August 2020.

In addition, Sensyne contributed to the UK's pandemic response by launching CVm-Health™ a remote monitoring system for COVID-19. This technology will support remote symptom data collection and analytics for a University of Oxford Phase 2 clinical trial in care homes of adalimumab to prevent respiratory failure due to COVID-19. The app is also being used by the University of Oxford in its FACTS clinical study evaluating the feasibility and acceptability of new point-of-care tests for regular asymptomatic COVID-19 testing amongst the student body.

Corporate activity

The senior management team was strengthened during the period following a number of new appointments that bring additional experience and expertise. These included the appointment of Michael Macdonnell, former director of Global Development at Google Health, as Chief Operating Officer who brings NHS and global technology company experience; Laura Hillier as General Counsel and Company Secretary who brings significant experience of pharma and corporate governance; Derek Baird as President of North America to lead the expansion of Sensyne into the United States; and Richard Pye as Chief Investment Officer with corporate finance and investor relations experience in the UK and US.

In December it was announced that Tony Bourne will join the Board as Independent Non-Executive Director and Chair of the Remuneration Committee from 31 January 2021.

Impact of COVID-19

We continue to monitor and respond to the rapidly changing global situation caused by the COVID-19 pandemic, including guidance and policy changes implemented by governments around the world. We have adapted our business practices to meet the new restrictions and the entire workforce continues to work remotely, but digitally connected which has increased productivity and presented recruitment opportunities. Our senior management team continue to assess the impact of the pandemic on present and future operations.

The pandemic is accelerating the interest in and adoption of digital medicine in both the healthcare and pharmaceutical sectors to improve healthcare outcomes and support research and development.

Sensyne has the opportunity to (i) place itself at the forefront of enabling clinicians and other healthcare practitioners to make better decisions with the help of AI-powered tools; and (ii) deploy Clinical AI to discover new medicines, to inform the planning and running of clinical trials and to identify substantial cost and efficiency savings to the wider pharmaceutical industry, while improving the likelihood of new medicines reaching patients.

Summary and Outlook

Sensyne has made significant progress during this period as it seeks to capitalise on its position at the heart of a fundamental shift in the healthcare and life science sectors towards greater use of big data analytics and clinical AI, a shift that has been accelerated by the COVID-19 pandemic. This progress included the significant increase in the size of the anonymised patient database, the number of NHS Trusts working with Sensyne and the global pharmaceutical companies approaching Sensyne to validate the Group's unique partnership model in clinical AI.

Sensyne plans to build on this progress by industrialising and scaling its datasets to power the SENSIGHT and SENSE platforms, as well as beginning to exploit the benefit of the strategic collaboration with Phesi, as Sensyne seeks to capitalise on the expanding number and range of commercial opportunities ahead of it. We look forward to reporting on our future progress.

Financial review

Revenue
Group revenue for the six months ended 31 October 2020 increased by £1.9m to £2.3m (HY20: £0.4m). The main growth factors are our clinical development projects in the Discovery Sciences segment such as with Bayer, Alexion and Roche. The strong performance of Discovery Sciences represents a change to the expected revenue mix at the beginning of the current financial year and is due to the delays the pandemic has caused to the launch of software products in the US and the Company's strategic decision to make its software free to use by the NHS for a 12-month period. The Group's ongoing contracts and business development activities provide confidence in meeting consensus revenue estimates for FY21.

Gross profit
Gross profit for the six months ended 31 October 2020 has increased by £1.1m to £1.3m (HY20: £0.2m) due to the increase in revenues. There was a slight decline in the gross margin to 57.5% (HY20: 62.2%). This is driven by the mix of clinical development services which yield varying margins on fixed fee contracts.

Operating expenses
Operating expenses for the six months ended 31 October 2020 increased by £4.8m to £14.9m (HY20: £10.1m).

Total research and development expenditure increased by £2.2m to £7.7m, of which £0.3m has been capitalised (HY20: £5.4m, of which £0.2m has been capitalised). This increase was primarily due to the continued investment in new R&D activities alongside ongoing development investment in live products, the operational cost of offering GDm-Heath and BPm-Health free of charge for one year to support the NHS during the COVID-19 pandemic as well an investment to improve NHS IT infrastructure to NHS Trust as part of on our ongoing commitment under SRAs.

Sales and marketing expenditure decreased by £0.1m to £0.6m (HY20: £0.7m). The decrease relates primarily to the impact of COVID-19 on attendance at national and international healthcare events and conferences.

Other general and administrative expenditure increased by £1.7m to £5.9m (HY20: £4.2m). The increase is driven by the continued investment to support the growth and development of the Group. This has included the strengthening of the senior management team with a number of key appointments being made during the period, alongside the continued use of interim contractors to support the execution of the Group's strategy across the business.

Exceptional items of £1.0m (HY20: £Nil) relate to professional fees and final payments incurred in the settlement of the legal case with the former CFO.

Adjusted operating loss
Adjusted operating loss is stated before interest, taxation, depreciation, amortisation, share-based payments, share of joint ventures losses and exceptional items.

Adjusted operating loss for the period increased by £2.2m to £9.5m (HY20: £7.4m) driven primarily by the increased costs described above.

Operating loss
The reported operating loss for the period was £13.6m (HY20: £9.8m).

The depreciation charge, including right of use assets, of £0.4m (HY20: £0.2m) increased by £0.2m, driven principally by the additional depreciation of £0.2m (HY20: £Nil) following the completion of the fit out and installation of IT infrastructure of our data centre at our Oxford Science Park leased premises in December 2019.

The amortisation of intangible assets of £2.2m (HY20: £2.0m) includes £1.8m (HY20: £1.8m) relating to acquired intangible assets, primarily the strategic research agreements, and £0.4m (HY20: £0.2m) relating to other intangible assets, primarily acquired and internally developed software.

Share based payment expenses for the period increased to £0.4m (HY20: £0.2m) because of the surrendering of options under our Group Share Option Plan 2018 ('CSOP 2018') which led to an acceleration of the remaining share option value in July 2020. A new Group Share Option Plan 2020 has since been introduced to all staff, except for Directors and Senior Management, which includes new terms and conditions.

Net finance costs
Finance costs for the period of £0.2m (HY20: £0.2m) relates to interest in respect of our Oxford Science Park lease liabilities. Finance income of £0.01m (HY20: £0.2m) relates to bank interest received over its cash balances. Net finance costs have increased by £0.2m (HY20: £Nil) due to the decrease in its cash balances and the Bank of England's cut in the base rates.

Cash flow
The Group had net cash outflows of £13.1m for the six months ended 31 October 2020 (HY20: £8.8m). The most significant movements relate to net cash flows used in operating activities of £12.4m (HY20: £7.5m) driven by the operating loss and a net working capital outflow of £1.9m (HY20: £0.3m).

Cash flows used in investing activities has decreased to £0.4m (HY20: £1.2m). Capital expenditure related primarily to the fit-out costs to provision our growing staff headcount with IT and office equipment to ensure safe remote working following a permanent change in our working arrangements in response to the COVID-19 pandemic. Software products invested a further £0.3m (HY20: £0.2m) in capitalised software development costs. Cash used in investment in Lab10x joint venture has decreased to £Nil (HY20: £0.6m) as the participants have jointly agreed to defer future payments until further notice.

Cash flows used in financing activities which relate to payments against lease liabilities has increased to £0.2m (HY20: £0.1) primarily due to the rent-free period ending in the previous year.

Financial position
As at 31 October 2020, cash and cash equivalents held were £18.6 million (30 April 2020: £31.7 million).

On 5 January 2021, post the period under review, total proceeds of £27.5 million were raised (before expenses) through a placing, subscription and open offer (the "Transaction") of new ordinary shares. Of these gross proceeds, approximately £2.0m were incurred in transaction-related fees and an investment of $10m (£7.7m including fees) was provided in relation to the equity acquisition and five-year strategic collaboration with Phesi, Inc that became effective on this date.

Share capital
On 5 January 2021, post the period under review, the Group issued 30,513,341 new £0.10 ordinary shares at a price of £0.90 per ordinary share as part of the Transaction. Following completion of the Transaction, the number of ordinary shares in issue was 159,084,855.

Independent review report to Sensyne Health Plc

Introduction
We have reviewed the condensed set of financial statements in the half-yearly financial report of Sensyne Health Plc (the 'company') for the six months ended 31 October 2020 which comprises the condensed consolidated interim statement of comprehensive income and consolidated interim statement of financial position. We have read the other information contained in the half-yearly financial report, and considered whether it contains any apparent misstatements or material inconsistencies with the information in the condensed set of financial statements.

Directors' responsibilities
The half-yearly financial report is the responsibility of, and has been approved by, the directors.

As disclosed in the annual financial statements of the group are prepared in accordance with International Financial Reporting Standards as adopted by the European Union. The condensed set of financial statements included in this half-yearly financial report has been prepared in accordance with International Accounting Standard 34, 'Interim Financial Reporting', as adopted by the European Union.

Our responsibility
Our responsibility is to express a conclusion to the company on the condensed set of financial statements in the half-yearly financial report based on our review.

Scope of review
We conducted our review in accordance with International Standard on Review Engagements (UK and Ireland) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity'. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK) and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The impact of macro-economic uncertainties on our review
Our review of the financial statements requires us to obtain an understanding of all relevant uncertainties, including those arising as a consequence of the effects of macro-economic uncertainties such as COVID-19 and Brexit. All reviews assess and challenge the reasonableness of estimates made by the directors and the related disclosures and the appropriateness of the going concern basis of preparation of the financial statements. All of these depend on assessments of the future economic environment and the company's future prospects and performance.

COVID-19 and Brexit are amongst the most significant economic events currently faced by the UK, and at the date of this report their effects are subject to unprecedented levels of uncertainty, with the full range of possible outcomes and their impacts unknown. We applied a standardised firm-wide approach in response to these uncertainties when assessing the company's future prospects and performance. However, no review should be expected to predict the unknowable factors or all possible future implications for a company associated with these particular events.

Conclusions relating to going concern
We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the directors' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the directors have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

In our evaluation of the directors' conclusions, we considered the risks associated with the company's business, including effects arising from macro-economic uncertainties such as COVID and Brexit, and analysed how those risks might affect the company's financial resources or ability to continue operations over the period of at least twelve months from the date when the financial statements are authorised for issue. In accordance with the above, we have nothing to report in these respects.

However, as we cannot predict all future events or conditions and as subsequent events may result in outcomes that are inconsistent with judgements that were reasonable at the time they were made, the absence of reference to a material uncertainty in this review report is not a guarantee that the company will continue in operation.

Conclusion
Based on our review, nothing has come to our attention that causes us to believe that the condensed set of financial statements in the half-yearly financial report for the six months ended 31 October 2020 is not prepared, in all material respects, in accordance with International Accounting Standard 34, 'Interim Financial Reporting', as adopted by the European Union and the Disclosure Guidance and Transparency Rules of the United Kingdom's Financial Conduct Authority.

Use of our report
This report is made solely to the company, as a body, in accordance with International Standard on Review Engagements (UK and Ireland) 2410, 'Review of Interim Financial Information performed by the Independent Auditor of the Entity'. Our review work has been undertaken so that we might state to the company those matters we are required to state to it in an independent review report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company as a body, for our review work, for this report, or for the conclusion we have formed.

Grant Thornton UK LLP
Statutory Auditor, Chartered Accountants
Reading
20 January 2021

Condensed Consolidated Interim Statement of Comprehensive Income

For the six-month period ended 31 October 2020

	Note	*Six months to 31-Oct-20 Unaudited £'000*	*Six months to 31-Oct-19 Unaudited £'000*	*Year to 30-Apr-20 Audited £'000*
Revenue	3	**2,318**	**392**	**2,050**
Cost of sales		(985)	(148)	(893)
Gross profit		**1,333**	**244**	1,157
Research and development expenses		(7,390)	(5,225)	(11,078)
Sales and marketing expenses		(619)	(668)	(1,364)
Other general and administration expenses		(5,936)	(4,188)	(9,754)
Other general and administration expenses – exceptional items	4	(977)	-	(1,410)
Operating loss		**(13,589)**	**(9,837)**	**(22,449)**
Finance costs		(173)	(171)	(347)
Finance income		10	154	254
Share of loss of joint ventures accounted for using the equity method		(57)	(40)	(89)
Loss before taxation		**(13,809)**	**(9,894)**	**(22,631)**
Income tax credit		-	-	792
Loss and total comprehensive loss for the period attributable to equity owners of the parent Company		**(13,809)**	**(9,894)**	**(21,839)**

Adjusted operating loss			
Operating loss	**(13,589)**	**(9,837)**	**(22,449)**
Exceptional items	977	-	1,410
Amortisation of intangible assets	2,248	2,009	4,214
Depreciation of property, plant and equipment	341	153	452
Depreciation of right of use assets	66	66	132
Share-based payments	425	245	235
Adjusted operating loss	**(9,532)**	**(7,364)**	**(16,006)**

Loss per share attributable to owners of the parent Company during the period (expressed in £ per share)				
Basic and diluted loss per share from continuing operations	2	**(0.11)**	**(0.08)**	**(0.17)**

The notes on pages 17 to 25 are an integral part of these Condensed Consolidated Interim Financial Statements.

Condensed Consolidated Interim Statement of Financial Position

As at 31 October 2020

	Note	*As at 31-Oct-20 Unaudited £'000*	*As at 31-Oct-19 Unaudited £'000*	*As at 30-Apr-20 Audited £'000*
Non-current assets				
Intangible assets		12,952	16,307	14,901
Property, plant and equipment		1,222	999	1,421
Right of use assets		1,550	1,683	1,618
Investment in joint venture		410	515	467
		16,134	**19,504**	**18,407**
Current assets				
Trade and other receivables		3,425	1,211	3,049
Corporation tax credit for research and development		-	208	820
Cash and cash equivalents		18,565	40,488	31,657
		21,990	**41,907**	**35,526**
Current liabilities				
Trade and other payables		(5,542)	(3,458)	(7,535)
Provisions		-	-	(397)
Short-term lease liability		(392)	(392)	(392)
		(5,934)	**(3,850)**	**(8,324)**
Net current assets		**16,056**	**38,057**	**27,202**
Total assets less current liabilities		**32,190**	**57,561**	**45,609**
Non-current liabilities				
Long-term lease liability		(1,688)	(1,772)	(1,717)
Provisions		(33)	-	(30)
		(1,721)	**(1,772)**	**(1,747)**
Net assets		**30,469**	**55,789**	**43,862**
Equity				
Share capital	5	12,857	12,857	12,857
Share premium account	5	59,485	59,485	59,485
Other reserves		(86,227)	(86,661)	(86,643)
Retained earnings		44,354	70,108	58,163
Total equity		**30,469**	**55,789**	**43,862**

The notes on pages 17 to 25 are an integral part of these Condensed Consolidated Interim Financial Statements.

Condensed Consolidated Interim Statement of Changes in Equity

For the six-month period ended 31 October 2020

	Note	*Share capital* *£'000*	*Share premium* *£'000*	*Other reserves* *£'000*	*Retained earnings* *£'000*	*Total* *£'000*
At 30 April 2019 (Audited)		**12,857**	**59,485**	**(86,930)**	**80,002**	**65,414**
Loss and total comprehensive loss for the period		-	-	-	(9,894)	(9,894)
Exchange difference on translation of foreign operations		-	-	24	-	24
Share-based payment charge		-	-	245	-	245
At 31 October 2019 (Unaudited)		**12,857**	**59,485**	**(86,661)**	**70,108**	**55,789**
Loss and total comprehensive loss for the period		-	-	-	(11,945)	(11,945)
Exchange difference on translation of foreign operations		-	-	28	-	28
Share-based payment charge		-	-	(10)	-	(10)
At 30 April 2020 (Audited)		**12,857**	**59,485**	**(86,643)**	**58,163**	**43,862**
Loss and total comprehensive loss for the period		-	-	-	(13,809)	(13,809)
Exchange difference on translation of foreign operations		-	-	(9)	-	(9)
Share-based payment charge		-	-	425	-	425
At 31 October 2020 (Unaudited)	5	**12,857**	**59,485**	**(86,227)**	**44,354**	**30,469**

Share premium represents the excess of the issue price over the par value on shares issued less transaction costs arising on the issue.

Other reserves include share option reserve, translation reserve and capital redemption reserve.

The notes on pages 17 to 25 are an integral part of these Condensed Consolidated Interim Financial Statements.

Condensed Consolidated Interim Statement of Cash Flows

For the six-month period ended 31 October 2020

	Six months to 31-Oct-20 Unaudited £'000	*Six months to 31-Oct-19 Unaudited £'000*	*Year to 30-Apr-20 Audited £'000*
Loss before taxation	**(13,809)**	**(9,894)**	**(22,631)**
Finance costs	173	171	347
Finance income	(10)	(154)	(254)
	(13,646)	**(9,877)**	**(22,538)**
Amortisation of intangible assets	2,248	2,009	4,214
Depreciation of property, plant and equipment	341	153	452
Depreciation of right of use assets	66	66	132
Share of loss of joint ventures accounted for using the equity method	57	40	89
Share-based payments	425	245	235
Operating loss before working capital movements	**(10,509)**	**(7,364)**	**(17,416)**
(Increase)/Decrease in trade and other receivables	444	(426)	(2,085)
Increase/(Decrease) in trade and other payables	(1,993)	90	4,167
Increase/(Decrease) in provisions	(394)	-	427
Cash used in operations	**(12,452)**	**(7,700)**	**(14,907)**
Finance income received	10	154	254
Total net cash outflow used in operating activities	**(12,442)**	**(7,546)**	**(14,653)**
Investing activities			
Purchase of property, plant and equipment	(142)	(395)	(1,116)
Purchase of other intangible assets	(299)	(248)	(1,047)
Investment in joint venture	-	(555)	(556)
Cash flows used in investing activities	**(441)**	**(1,198)**	**(2,719)**
Financing activities			
Payments against lease liability	(202)	(53)	(267)
Net cash outflow from financing activities	**(202)**	**(53)**	**(267)**
Net decrease in cash and cash equivalents	**(13,085)**	**(8,797)**	**(17,639)**
Cash and cash equivalents at the start of the period	31,657	49,252	49,252
Effect of foreign exchange rate change	(7)	33	44
Cash and cash equivalents at the end of the period	**18,565**	**40,488**	**31,657**

The notes on pages 17 to 25 are an integral part of these Condensed Consolidated Interim Financial Statements.

Notes to the Condensed Consolidated Interim Financial Information
For the six-month period ended 31 October 2020

1. Summary of significant accounting policies

General information

Sensyne Health plc (the "Company") is a public company limited by shares, registered in England and Wales, incorporated and domiciled in the United Kingdom, whose shares are publicly traded on the AIM segment of the London Stock Exchange. The address of its registered office is Schrödinger Building, Heatley Road, Oxford Science Park, Oxford, England OX4 4GE.

The Company and its subsidiary undertakings are referred to in this report as the Group.

The Condensed Consolidated Interim Financial Statements were approved for issue on 20 January 2021.

The financial information for the six months ended 31 October 2020 is unaudited and does not comprise statutory accounts within the meaning of section 434 of the Companies Act 2006, but has been reviewed in accordance with ISRE 2410 by the Group's statutory auditors. The Group's statutory financial statements for the year ended 30 April 2020 have been filed with the Registrar of Companies. The auditor's report on those financial statements was unqualified and did not contain statements under Section 498 of the Companies Act 2006.

Basis of preparation

The Condensed Consolidated Interim Financial Statements for the six months ended 31 October 2020 included in this Interim Report have been prepared in accordance with IAS 34 "Interim Financial Reporting" (IAS 34) as adopted by the European Union and have been prepared on a going concern basis as described further below.

Going concern

The Board has prepared the Condensed Consolidated Interim Financial Information on a going concern basis, which is considered to be appropriate.

In January 2021, the Company completed a Placing, Open Offer and Subscription equity fund raise that led to the receipt of net proceeds of £25.5m after transaction-related fees of approximately £2m.

In assessing the appropriateness of the going concern assumption, the Board has considered the cash requirements of the Group and Company, taking into account but not limited to, the unprecedented circumstances caused by the COVID-19 pandemic and the UK's departure from the EU on the future viability of the Group for the 15 month period ended 30 April 2022.

The Board have prepared and reviewed detailed financial forecasts (as part of the longer term plan), that have been sensitised, to reflect the plausible downside scenarios caused by the COVID-19 pandemic and UK's exit from the EU as well as the risks and uncertainties associated with the Group as set out in the Group's latest Annual Report. These forecasts demonstrate that the Group and Company has sufficient cash runway to meets its obligations as they fall due for a period of at least 12 months from the date of signing this interim report.

As such, the Board are satisfied that the Group and Company has adequate resources to continue to operate for the foreseeable future. For this reason they continue to adopt the going concern basis for preparing the interim financial statements.

Accounting policies

The accounting policies and methods of computation followed in these Condensed Consolidated Interim Financial Statements are the same as applied in the Group's latest annual audited Financial Statements.

Critical accounting judgements and sources of estimation uncertainty

The preparation of Interim Financial Statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results might differ from these estimates.

In preparing these condensed interim financial statements, the significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the Consolidated Financial Statements for the year ended 30 April 2020 apart from the additional policy outlined below:

Critical judgement – share based payments

In the period, some employees surrendered their existing share options and were then subsequently granted new options under revised terms and conditions.

The directors of the Group assessed whether or not these events constituted a modification of the existing scheme or a cancellation and re-grant of options under a new scheme. In making their judgement, the directors considered the substance of the underlying transaction and relevant terms and conditions of each scheme. After assessment, the directors concluded that the surrendering of options and subsequent grant of options was a cancellation and a new grant. Therefore under IFRS 2 Share Based Payments the remaining total fair value of the surrendered options was expensed immediately, reflecting an acceleration of the vesting period for those options, and a separate charge accounted for to reflect a new scheme.

2. Loss per share

Basic loss per share is calculated by dividing the loss attributable to equity owners of the Company by the weighted average number of Ordinary Shares in issue during the period.

	Six months to 31-Oct-20 Unaudited	*Six months to 31-Oct-19 Unaudited*	*Year to 30-Apr-20 Audited*
Weighted average number of shares in issue for the purpose of basic and adjusted loss per share	**128,571,514**	**128,571,514**	128,571,514
Loss attributable to equity owners of the parent Company (£000)	(13,809)	(9,894)	(21,839)
Basic loss per share (£)	**(0.11)**	**(0.08)**	**(0.17)**
Adjusting items including exceptional items, amortisation and depreciation (£'000)	4,057	2,530	5,833
Adjusted loss attributable to equity owners of the parent Company (£'000)	(9,532)	(7,364)	(16,006)
Adjusted basic loss per share (£)	**(0.07)**	**(0.06)**	**(0.12)**

As net losses were recorded in the six months ended 31 October 2020 and in each of the comparative periods, the dilutive potential shares are anti-dilutive and therefore were excluded from the loss per share calculation.

3. **Segmental operations**

In accordance with IFRS 8, the Group's operating segments are based on the information reviewed by the Board of Directors, which represents the chief operating decision maker who is responsible for allocating resources and assessing performance. The business comprises two operating segments:

- Software Products - product licensing revenue earned from licences granted under licensing agreements, including upfront payments.
- Discovery Sciences - consultant services revenue earned through contracts with pharmaceutical companies to develop Clinical AI technology.

Costs shared between the segments are not allocated to individual segments for decision making purposes. These are disclosed under the column headed "Corporate & Support".

Six months ended 31 October 2020

	Software Products	*Discovery Sciences*	*Corporate & Support*	*Total*
	£'000	*£'000*	*£'000*	*£'000*
Revenue	**105**	**2,213**	**-**	**2,318**
Cost of sales	(42)	(943)	-	(985)
Gross profit	**63**	**1,270**	**-**	**1,333**
Research and development expenses	(3,486)	(3,551)	(353)	(7,390)
Sales and marketing expenses	(233)	(188)	(198)	(619)
Other general and administration expenses	(791)	(207)	(4,938)	(5,936)
Other general and administration expenses – exceptional items	-	-	(977)	(977)
Operating loss	**(4,447)**	**(2,676)**	**(6,466)**	**(13,589)**
Finance costs	-	(53)	(120)	(173)
Finance income	-	-	10	10
Share of loss of joint ventures accounted for using the equity method	(57)	-	-	(57)
Loss before taxation	**(4,504)**	**(2,729)**	**(6,576)**	**(13,809)**
Income tax credit	-	-	-	-
Loss and total comprehensive loss for the period attributable to equity owners of the parent Company	**(4,504)**	**(2,729)**	**(6,576)**	**(13,809)**

Adjusted operating loss				
Operating loss	**(4,447)**	**(2,676)**	**(6,466)**	**(13,589)**
Exceptional items	-	-	977	977
Amortisation of intangible assets	498	1,750	-	2,248
Depreciation of property, plant and equipment	-	-	341	341
Depreciation of right of use assets	-	20	46	66
Share-based payments	209	(69)	285	425
Adjusted operating loss	**(3,740)**	**(975)**	**(4,817)**	**(9,532)**

Revenue is analysed geographically by region as follows:

	Six months to 31-Oct-20 Unaudited £'000	*Six months to 31-Oct-19 Unaudited £'000*	*Year to 30-Apr-20 Audited £'000*
United Kingdom	105	392	387
Europe	2,051	-	1,606
United States	57	-	57
	2,213	**392**	**2,050**

The Group has applied the European Securities and Markets Authority (ESMA) "Guidelines on Alternative Performance Measures" in these annual results. In the context of these results, an alternative performance measure (APM) is a financial measure of historical or future financial performance, position or cash flows of the Group which is not a measure defined or specified in IFRS.

Six months ended 31 October 2019

	Software Products £'000	*Discovery Sciences £'000*	*Corporate & Support £'000*	*Total £'000*
Revenue	**250**	**142**	**-**	**392**
Cost of sales	(89)	(59)	-	(148)
Gross profit	**161**	**83**	**-**	**244**
Research and development expenses	(2,188)	(2,623)	(414)	(5,225)
Sales and marketing expenses	(210)	(390)	(68)	(668)
Other general and administration expenses	(267)	(58)	(3,863)	(4,188)
Other general and administration expenses – exceptional items	-	-	-	-
Operating loss	**(2,504)**	**(2,988)**	**(4,345)**	**(9,837)**
Finance costs	-	(54)	(117)	(171)
Finance income	-	-	154	154
Share of loss of joint ventures accounted for using the equity method	(40)	-	-	(40)
Loss before taxation	**(2,544)**	**(3,042)**	**(4,308)**	**(9,894)**
Income tax credit	-	-	-	-
Loss and total comprehensive loss for the period attributable to equity owners of the parent Company	**(2,544)**	**(3,042)**	**(4,308)**	**(9,894)**

Adjusted operating loss				
Operating loss	**(2,504)**	**(2,988)**	**(4,345)**	**(9,837)**
Exceptional items	-	-	-	-
Amortisation of intangible assets	259	1,750	-	2,009
Depreciation of property, plant and equipment	-	-	153	153
Depreciation of right of use assets	-	-	66	66
Share-based payments	159	(74)	160	245
Adjusted operating loss	**(2,086)**	**(1,312)**	**(3,966)**	**(7,364)**

Year ended 30 April 2020

	Software Products	*Discovery Sciences*	*Corporate & Support*	*Total*
	£'000	*£'000*	*£'000*	*£'000*
Revenue	**374**	**1,676**	**-**	**2,050**
Cost of sales	(179)	(714)	-	(893)
Gross profit	**195**	**962**	**-**	1,157
Research and development expenses	(4,932)	(5,347)	(799)	(11,078)
Sales and marketing expenses	(552)	(777)	(35)	(1,364)
Other general and administration expenses	(1,009)	(629)	(8,116)	(9,754)
Other general and administration expenses – exceptional items	-	-	(1,410)	(1,410)
Operating loss	**(6,298)**	**(5,791)**	**(10,360)**	**(22,449)**
Finance costs	-	(108)	(239)	(347)
Finance income	-	-	254	254
Share of loss of joint ventures accounted for using the equity method	(89)	-	-	(89)
Loss before taxation	**(6,387)**	**(5,899)**	**(10,345)**	**(22,631)**
Income tax credit	511	216	65	792
Loss and total comprehensive loss for the period attributable to equity owners of the parent Company	**(5,876)**	**(5,683)**	**(10,280)**	**(21,839)**

Adjusted operating loss				
Operating loss	**(6,298)**	**(5,791)**	**(10,360)**	**(22,449)**
Exceptional items	-	-	1,410	1,410
Amortisation of intangible assets	714	3,500	-	4,214
Depreciation of property, plant and equipment	-	-	452	452
Depreciation of right of use assets	-	40	92	132
Share-based payments	22	(10)	223	235
Adjusted operating loss	**(5,562)**	**(2,261)**	**(8,183)**	**(16,006)**

4. Exceptional items

	Six months to 31-Oct-20 Unaudited £'000	*Six months to 31-Oct-19 Unaudited £'000*	*Year to 30-Apr-20 Audited £'000*
Professional fees incurred following departure of former CFO	**977**	-	1,410
	977	-	1,410

In the six months to 31 October 2020 professional fees were incurred in respect to the legal claim started in the previous financial year.

During the year ended 30 April 2020 a legal claim was made by the former CFO, Lorimer Headley. Professional fees were incurred by the Company to represent the Company and its Directors and to conduct an independent internal investigation in respect to claims made against the Company and its Directors. In August 2020, the Company agreed to make a payment as compensation for loss of office of £150,000 (plus £17,000 in employers national insurance contributions) and a contribution of £200,000 towards legal fees. As part of that settlement the Board has also agreed to provide outplacement assistance up to a value of £30,000.

There were no exceptional costs in the six months to 31 October 2019.

5. Share Capital

	Number of shares	**Nominal value £'000**	**Share Premium** £'000
Authorised, allotted and fully paid			
Ordinary Shares of £0.10 each	128,571,514	12,857	59,485
	128,571,514	**12,857**	**59,485**

	Share capital £'000	**Share premium £'000**
At 31 October 2019 (Unaudited)	**12,857**	**59,485**
At 30 April 2020 (Audited)	**12,857**	**59,485**
At 31 October 2020 (Unaudited)	**12,857**	**59,485**

6. Related parties

Included within trade and other payables is a balance due to Drayson Technologies (Europe) Limited of £1,000 (31 October 2019: £165,000; 30 April 2020: £nil). This company was demerged from the Group during the year ended 30 April 2019 and is a related party by virtue of common control.

Expenditure of £14,000 incurred on behalf of the Group were recharged from Drayson Technologies (Europe) Limited (31 October 2020: £Nil; 30 April 2020: £359,000).

Oxford Sciences Innovation Plc (OSI) is a related party through the joint venture for LAB10x. During the period, revenue of £47,000 (31 October 2019: £120,000; 30 April 2020: £162,000) was recognised in relation to support and maintenance and consultancy services provided to OSI. In addition, £60,000 (31 October 2019: £Nil; 30 April 2020: £73,000) was billed to OSI for the reimbursement of expenditure incurred on behalf of the joint venture, Lab10x.

Included within trade and other receivables at 31 October 2020, is a trade receivable balance of £92,000 (31 October 2019: £Nil; 30 April 2020: £23,000) and accrued income balance of £22,000 (31 October 2019: £120,000; 30 April 2020: £54,000) due from OSI.

During the period, £Nil (31 October 2019: £Nil, 30 April 2020: £555,000) was paid to OSI in relation to the Lab10x joint venture agreement. In agreement with all members of the joint venture, future payments as obligated under this arrangement have been deferred.

7. Principal risks and uncertainties

The 2020 Annual Report sets out on pages 25 to 28 the principal risks and uncertainties that could impact the business. There are no changes to these risks and uncertainties.

8. Subsequent events

On 13 November 2020, Sensyne announced the appointment of Derek Baird to its senior management team as President, North America from 1 December 2020.

On 16 November 2020, Sensyne announced a five-year non-exclusive Strategic Research Agreement ("SRA") with Somerset NHS Foundation Trust for which they will be issued with 1,428,571 £0.10 ordinary shares in the Company at a price of £1.75 per share, subject to the satisfaction of certain conditions including receipt of a s593 report by the Company.

On 25 November 2020, Sensyne announced a five-year non-exclusive SRA with Hampshire Hospitals NHS Foundation Trust for which they will be issued with 1,428,571 £0.10 ordinary shares in the Company at a price of £1.75 per share, subject to the satisfaction of certain conditions including receipt of a s593 report by the Company.

On 18 December 2020, Sensyne announced the appointment of Tony Bourne to the Board as Independent Non-Executive Director with effect from 31 January 2021. He will also serve as Chair of the Remuneration Committee.

On 5 January 2021, Sensyne completed a placing, subscription and open offer (the "Transaction") on the AIM market of the London Stock Exchange issuing 30,513,341 new £0.10 ordinary shares at a price of £0.90 per share. Aggregate gross proceeds of £27.5 million were raised for the Company and directly attributable transaction costs of £2.0 million were incurred. On 5 January 2021, a strategic collaboration with Phesi, Inc, a specialist clinical trials company incorporated in United States of America, became effective following the completion of the Transaction. The Phesi agreement comprises a strategic alliance agreement and a securities purchase agreement. Under the strategic alliance agreement, Phesi and Sensyne will collaborate on an exclusive basis to offer synthetic clinical trial arms and clinical decision support tools combining clinical trial data with real world data. The initial term of the exclusive strategic collaboration will be 5-years with an automatic renewal for successive two-year periods unless terminated. Joint projects with pharmaceutical company clients will be based on a revenue share model. Under the terms of the securities purchase agreement, Sensyne has made a $10 million equity investment into Phesi for 10% of its fully-diluted share capital, the proceeds of which are to be used for specific purposes aimed towards enhancing the Phesi clinical trials data analytics offering and activities that are connected to the strategic collaboration. The securities purchase agreement also provides that Lord Drayson will join Phesi's board of directors.

On 20 January 2021, Sensyne announced a five-year non-exclusive SRA with The Royal Wolverhampton NHS Trust for which they will be issued with 1,428,571 £0.10 ordinary shares in the Company at a price of £1.75 per share, subject to the satisfaction of certain conditions including receipt of a s593 report by the Company.

Appendix – Summary of Recent News

A summary of Sensyne recent news highlights for the current 2020/21 financial year

20-Apr-20	Launch of **CVm-Health™** 'Good Neighbour' app	Link
05-May-20	Launch of new **BPm-Health™** remote monitoring system for the management of blood pressure in pregnancy in response to COVID-19 pandemic	Link
14-May-20	Trading and Business Update	Link
19-May-20	Launch of **CVm-Health™** 'Good Neighbor' app in the United States with support from Microsoft and Cognizant	Link
19-Aug-20	Development of '**DBm-Health™**' a new software product for people with or at risk of diabetes	Link
03-Sep-20	UK launch of '**SENSE™**' - a clinical algorithm engine, created in partnership with Microsoft	Link
10-Sep-20	Appointment Chief Operating Officer	Link
29-Sep-20	Acacia Investment in Sensyne	Link
30-Sep-20	Full Year Results	Link
30-Sep-20	University of Oxford collaboration on Phase II clinical trial in care homes to prevent respiratory failure due to COVID-19	Link
01-Oct-20	Data access agreement with **NHS Greater Glasgow and Clyde**	Link
23-Oct-20	Agreement with **Bristol Myers Squibb** to apply machine learning for rare blood disease research	Link
26-Oct-20	**Milton Keynes University Hospital** sign Strategic Research Agreement	Link
28-Oct-20	Strategic partnership with Microsoft and co-development of cloud and machine learning capabilities	Link
02-Nov-20	**CVm-Health+** software application to facilitate rapid COVID-19 antigen testing study by the University of Oxford	Link
13-Nov-20	Sensyne Health appoints President, North America, to lead US expansion	Link
16-Nov-20	**Somerset NHS Foundation Trust** sign Strategic Research Agreement	Link
16-Nov-20	Sensyne Health achieves five million patient target set at IPO	Link

25-Nov-20	**Hampshire Hospitals NHS Foundation Trust** sign Strategic Research Agreement	Link
15-Dec-20	Sensyne Health launches first digital health product in the U.S	Link
18-Dec-20	Tony Bourne joins as Independent Non-Executive Director	Link
04-Jan-21	Result of Open Offer	Link
04-Jan-21	Completion of Fundraising and Strategic Collaboration with Phesi	Link
14-Jan-21	**Launch of MagnifEye** smartphone application to automate the reading and Big Data analysis of lateral flow tests using deep learning AI	Link
20-Jan-21	**The Royal Wolverhampton NHS Trust** sign Strategic Research Agreement	Link

For more information on availability, please contact:
info@sensynehealth.com

www.sensynehealth.com